Sangui Biotech International Inc. reported earnings results for the first quarter ended September 30, 2016. For the quarter, the company achieved revenues from royalty income and product sales of USD 9,711 against USD 11.471 a year ago. The operating loss decreased compared to the prior year quarter by USD 91,533 to USD 69,893.

The company expects for the further development of the fiscal year 2017 rising sales of Granulox and accordingly increasing royalty income. This forecast is based on the successful integration of new sales partners (UK and Southeast Asia) as well as positive developments in already developed sales areas.